ProCE Banner Activity

CME

Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on optimizing treatment for patients with acute leukemias.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: October 07, 2020

Expiration: October 06, 2021

No longer available for credit.

Share

Faculty

David Marks

David Marks, MD, PhD

Professor of Haematology and Stem Cell Transplanation
Department of Haematology and BMT
University of Bristol
University Hospitals Bristol NHS
Bristol, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Target Audience

This program is intended for global hematologists, medical oncologists, and other healthcare clinicians who care for patients with acute leukemias.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the available evidence to optimally integrate antibody–drug conjugates and other immune-based therapies in ALL
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with relapsed/refractory ALL, considering the available clinical evidence, new drug approvals, and demands on health services resource utilization
  • Discuss how to effectively sequence treatment with novel immunotherapies in ALL
  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions

  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/ refractory AML without FLT3 or IDH1/2 mutations
  • Plan evidence-based therapeutic strategies using novel targeted agents or formulations and refinements of conventional chemotherapy for AML

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

David Marks, MD, PhD

Professor of Haematology and Stem Cell Transplanation
Department of Haematology and BMT
University of Bristol
University Hospitals Bristol NHS
Bristol, United Kingdom

David Marks, MD, PhD, has disclosed that he has received consulting fees from Amgen, Novartis, and Pfizer.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 07, 2020, through October 06, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations in the care of their patients with AML and ALL.